GlassScriptPhysician profile
Marlene V Rodriguez
NPI 1093822090
$6,131.39
in general payments reported to CMS, 2019-2025
44 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $618 · 2021: $323 · 2022: $127 · 2023: $1,113 · 2024: $1,518 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.45 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $775.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $477.93 | 2019-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $426.23 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $418.76 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $390.91 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.66 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $347.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $331.63 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $259.08 | 2019-2025 | |
| Daiichi Sankyo INC. | $252.31 | 2019-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.96 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $158.28 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $157.61 | 2023-2025 | Veozah |
| Corcept Therapeutics | $149.14 | 2019-2025 | Korlym |
| Exact Sciences Corporation | $146.84 | 2024-2025 | Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.